Mesenchymal Stem Cells Therapy in critical COVID-19 patient: a case report
DOI:
https://doi.org/10.12928/admj.v3i1.6460Keywords:
ARDS; MODS; Stem Cell; cytokine storm; Natural KillerAbstract
COVID-19 pneumonia with critical symptoms causes acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndromes (MODS) which can be severe complications until death. One therapy for Covid-19 critical was to suppress the effects of cytokine storms, which was administered by Mesenchymal Stem Cells therapy. In this case, we will report a case of COVID-19 with a critical patient that was given MSC therapy there were good outcomes in this case which were improvement of the clinical symptoms and prevent death.
ABSTRAK
Pneumonia COVID-19 dengan gejala kritis menyebabkan sindrom gangguan pernapasan akut (ARDS) dan sindrom disfungsi organ multipel (MODS) yang dapat menjadi komplikasi berat hingga kematian. Salah satu terapi kritis Covid-19 adalah menekan efek badai sitokin, yang dilakukan dengan terapi Sel Punca Mesenkim. Dalam kasus ini, kami akan melaporkan kasus COVID-19 dengan pasien kritis yang diberikan terapi MSC ada hasil yang baik dalam kasus ini yaitu perbaikan gejala klinis dan mencegah kematian
References
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) : A Review W. Joost Wiersinga, MD, PhD; Andrew Rhodes, MD, PhD; Allen C. Cheng, MD, PhD;Sharon J. Peacock, PhD; Hallie C. Prescott, MD, MSc. JAMA : 2020
Cytokine Storm in COVID-19: An Overview, Mechanism,ovid 19 Treatment Strategies, and Stem Cell Therapy Perspective. Nuriza Ulul Azmi1*, Meidi Utami Puteri2, Donny Lukmanto. Pharmaceutical Sciences and Research (PSR), 7(Special Issue on COVID-19), 2020, 1 – 11
Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Rohit Shetty1, Ponnalagu Murugeswari2, Koushik Chakrabarty3, Chaitra Jayadev, Himanshu Matalia1, Arkasubhra Ghosh3, Debashish Das
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0
Khoury, M., Cuenca, J., Cruz, F. F., Figueroa, F. E., Rocco, P. R. M., & Weiss, D. J. (2020). Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19. European Respiratory Journal, 2000858. doi:10.1183/13993003.00858-2020
Zakrzewski, W. et al., 2019. Stem cells: Past, present, and future. Stem Cell Research & Therapy, 10(1), pp.1–22.
Chouw, A. et al., 2021. Potency of mesenchymal stem cell and its secretome in treating COVID-19. Regenerative Engineering and Translational Medicine.
Zheng, G., Huang, L., Tong, H., Shu, Q., Hu, Y., Ge, M., Xu, J. (2014). Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respiratory Research, 15(1), 39. doi:10.1186/1465- 9921-15-39
Basiri, A. et al., 2021. Stem cell therapy potency in personalizing severe COVID-19 treatment. Stem Cell Reviews and Reports, 17(1), pp.193–213.
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019). Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine, 4(1), 22. doi:10.1038/ s41536-019-0083-6
Jiang, W., & Xu, J. (2020). Immune modulation by mesenchymal stem cells. Cell Proliferation, 53(1), e12712. doi:10.1111/cpr.12712
Xu, R., Feng, Z., Wang, Fu-Sheng. (2022). Mesenchymal stem cell treatment for COVID-19. eBioMedicine ; 77:103920. https://dor.org./10.1016/j.ebiom.2022.103920
Arabpour, E., Khoshdel, S., Tabatabaie, N., Akhgarzad, A., Zangiabadian, M., & Nasiri, M. J. (2021). Stem cells therapy for COVID-19: A systematic review and meta-analysis. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.737590
Mahendiratta S, Bansal S, Sarma P, Kumar H, Choudhary G, Kumar S, et al. Stem cell therapy in COVID-19: pooled evidence from SARS-CoV-2, SARSCoV, MERS-CoV and ARDS: a systematic review. Biomed Pharmacother. (2021) 137:111300. doi: 10.1016/j.biopha.2021.111300
D. Rubin, U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study, (2020). https://www.globenewswire.com/news-release/2020/05/08/ 2030212/0/en/U-S-FDA-Clears-Pluristem-s-IND-Application-for-Phase-IICOVID-19-Study.html. (Accessed 13 January 2022).
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet, 395(10229), 1033- 1034.
Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. Journal of Infection, 80(6), 607-613.
Sidhu, K., (2020). The cytokine storm in COVID-19 patients amenable to stem cell treatment: A perspective. Stem Cell and Regenerative Medicine, 4(1), pp.1–11
Durand, N., Mallea, J. & Zubair, A.C., (2020). Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. npj Regenerative Medicine, 5(1), pp.1–9.
Shu L, Niu C, Li R, Huang T, Wang Y, Ji N, et al. (2020). Treatment of severe COVID19 with human umbilical cord mesenchymal stem cells. Res Square. 11:1–11. doi: 10.21203/rs.3.rs-23696/v
Câmara, D.A. et al., (2021). A COVID-19 overview and potential applications of cell therapy. Biologics, 1(2), pp.177–188.
Leng, Z.; et al. (2020). Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis.: 11, 216–228. [CrossRef] [PubMed]).
Arabpour, E. et al., (2021). Stem cells therapy for COVID-19: A systematic review and meta-analysis. Frontiers in Medicine, 8, pp.1–13.
Moll, G., Ankrum, J. A., Kamhieh-Milz, J., Bieback, K., Ringdén, O., Volk, H.-D., Reinke, P. (2019). Intravascular mesenchymal stromal/stem cell therapy product diversification: Time for new clinical guidelines. Trends in Molecular Medicine, 25(2), 149-163. doi:https://doi.org/10.1016/j.molmed.2018.12.006
Golchin, A., Seyedjafari, A., Ardeshirylajimi, A. (2020). Mesenchiymal Stem Cell Therapy for COVID-19 : Present or Future. Stem Cell Reviews and Reports. https://doi.org./10.1007/s12015-020-09973-w
Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM, Caplan AI, Kurtzberg J, Zubair AC, Kubrova E, Engelberg-Cook E, Nayfeh T, Shah VP, Hill JC, Wolf ME, Prokop LJ, Murad MH, Sanfilippo FP. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020 Sep;9(9):1007-1022. doi: 10.1002/sctm.20-0146. Epub 2020 May 29. PMID: 32472653; PMCID: PMC7300743.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Novi Sukirto, Zainul Arifin, Sumardi, Barkah Purwanto, Auliya Azisah Mansur, Naila Sistharani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License and Copyright Agreement
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal. Please also carefully read Ahmad Dahlan Medical Journal posting Your Article Policy.
- That it is not under consideration for publication elsewhere.
- That its publication has been approved by all the author(s) and by the responsible authorities - tacitly or explicitly - of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
Copyright
Authors who publish with Ahmad Dahlan Medical Journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
